ARQTArcutis Biotherapeutics, Inc.

Healthcare

$31.21+49% 1Y

$31.21

$19.5052 weeks$32.80

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.

1 good, 1 to watch, 1 without data

What the price assumes~+27% a year

Priced for ~27% a year FCF growth. The price demands less than its three-year revenue growth of 241% a year, expectations look modest.

Vs sector (EV/EBIT)110.7×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 3% of the market

FCF yieldbottom 5% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What ARQT's price assumes

Arcutis Biotherapeutics, Inc. trades at 149× earnings against 19.8× for the median Biotechnology name, more expensive than its own group.

149

Trailing P/E · Biotechnology median 19.8 · 7.51× the median: the market pays up for this one

Price / sales: 8.45
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 1.0%
Free cash flow yield · Biotechnology median 4.3%
Growth the price implies: +27%
Growth the price implies · The price pays for +27% free cash flow growth a year for a decade; revenue has grown 241% a year over the last three.